An increasing number of reports have described the COVID-19 associated pulmonary aspergillosis (CAPA) as being a further contributing factor to mortality. Based on a recent consensus statement supported by international medical mycology societies, it has been proposed to define CAPA as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Considering current challenges associated with proven diagnoses there is pressing need to study the epidemiology of proven CAPA.
Proven COVID-19-associated pulmonary aspergillosis in patients with severe respiratory failure
Fortarezza, Francesco;Pezzuto, Federica;Lunardi, Francesca;Giraudo, Chiara;Del Vecchio, Claudia;Sella, Nicolò;Cattelan, Annamaria;Vedovelli, Luca;Gregori, Dario;Vettor, Roberto;Navalesi, Paolo;Calabrese, Fiorella
2021
Abstract
An increasing number of reports have described the COVID-19 associated pulmonary aspergillosis (CAPA) as being a further contributing factor to mortality. Based on a recent consensus statement supported by international medical mycology societies, it has been proposed to define CAPA as possible, probable, or proven on the basis of sample validity and thus diagnostic certainty. Considering current challenges associated with proven diagnoses there is pressing need to study the epidemiology of proven CAPA.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Fortarezza Proven COVID- 19— associated pulmonary aspergillosis in patients with severe respiratory failure Mycoses 2021.pdf
accesso aperto
Tipologia:
Published (publisher's version)
Licenza:
Creative commons
Dimensione
1.53 MB
Formato
Adobe PDF
|
1.53 MB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
